Published in J Virol on September 01, 2001
General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol (2007) 1.01
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology (2000) 0.90
Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression. Clin Vaccine Immunol (2015) 0.86
DNA vaccines in veterinary use. Expert Rev Vaccines (2009) 0.86
The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma. World J Gastroenterol (2002) 0.85
Construction of an expression system for bioactive IL-18 and generation of recombinant canine distemper virus expressing IL-18. J Vet Med Sci (2014) 0.77
Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection. BMC Vet Res (2012) 0.75
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell (1977) 18.95
A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res (1995) 7.08
Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49
Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol (1996) 2.67
Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol (1995) 2.57
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol (1997) 2.29
Interleukin-12. J Leukoc Biol (1994) 2.22
Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol (1995) 2.21
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med (1997) 2.12
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Determinants of the host range of feline leukaemia viruses. J Gen Virol (1973) 1.64
Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol (1997) 1.60
DNA vaccines. Life Sci (1997) 1.53
In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol (1997) 1.53
Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol (1998) 1.50
IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol (1999) 1.48
Feline leukaemia virus: generation of pathogenic and oncogenic variants. Curr Top Microbiol Immunol (1991) 1.32
Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol (1998) 1.30
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol (1999) 1.23
Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. J Immunol (1985) 1.22
Protection against feline leukemia by vaccination with a subunit vaccine. Infect Immun (1981) 1.16
Serological responses of cats to feline immunodeficiency virus. AIDS (1990) 1.14
Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther (1995) 1.11
Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol (1997) 1.11
Interferon-gamma. Curr Opin Immunol (1992) 1.10
DNA vaccines. Pharmacol Ther (1997) 1.09
Modulating the immune response to genetic immunization. FASEB J (1998) 1.06
Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol (1997) 1.04
Feline leukemia virus infection: age-related variation in response of cats to experimental infection. J Natl Cancer Inst (1976) 1.03
Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J Immunol (1998) 1.03
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol (1993) 1.01
DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol (1998) 1.01
Detection of transient and persistent feline leukaemia virus infections. Vet Rec (1982) 1.00
Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine. Vet Rec (1996) 0.98
Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine (1997) 0.97
Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Vet Immunol Immunopathol (1986) 0.97
Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol (1997) 0.97
Safety and efficacy studies of live- and killed-feline leukemia virus vaccines. Am J Vet Res (1979) 0.96
Do DNA vaccines induce autoimmune disease? Hum Gene Ther (1997) 0.95
Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology (2000) 0.90
Feline leukaemia virus: a review of immunity and vaccination. J Small Anim Pract (1997) 0.89
DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol (1997) 0.89
Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine (1999) 0.88
Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy (1997) 0.87
Protection against feline leukemia virus infection by use of an inactivated virus vaccine. J Am Vet Med Assoc (1991) 0.87
Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats. Vaccine (1991) 0.86
Immunogenicity and efficacy of a commercial feline leukemia virus vaccine. J Vet Intern Med (1993) 0.84
Recovery of feline leukaemia virus from non-viraemic cats. Vet Rec (1983) 0.84
Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. Vaccine (1989) 0.84
Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Virus Res (1987) 0.83
DNA vaccination using expression vectors carrying FIV structural genes induces immune response against feline immunodeficiency virus. Vaccine (1997) 0.81
The relevance of feline retroviruses to the development of vaccines against HIV. AIDS Res Hum Retroviruses (1996) 0.81
Duration of the latent state in feline leukaemia virus infections. Vet Rec (1985) 0.81
Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure. J Am Vet Med Assoc (1991) 0.81
Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection. J Am Vet Med Assoc (1991) 0.81
Feline leukemia virus vaccine development. J Am Vet Med Assoc (1991) 0.80
Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. J Am Vet Med Assoc (1991) 0.80
The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. J Gen Virol (1992) 0.80
Study of feline leukemia virus immunity. J Am Vet Med Assoc (1991) 0.79
Development of a whole killed feline leukemia virus vaccine. J Am Vet Med Assoc (1991) 0.79
Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection. J Virol (1997) 0.78
Post-exposure treatment with monoclonal antibodies in a retrovirus system: failure to protect cats against feline leukemia virus infection with virus neutralizing monoclonal antibodies. Int J Cancer (1986) 0.78
Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial. Vaccine (1997) 0.77
Efficacy of recombinant feline leukemia virus vaccines. AIDS Res Hum Retroviruses (1996) 0.77
Nucleotide and predicted peptide sequence of feline interferon-gamma (IFN-gamma). DNA Seq (1995) 0.77
Development of a genetically engineered vaccine against feline leukemia virus infection. J Am Vet Med Assoc (1991) 0.77
Efficacy of a feline leukemia virus vaccine in a natural exposure challenge. J Vet Intern Med (1990) 0.76
Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector. Vaccine (1996) 0.76
Randomized blind trial of a commercial FeLV vaccine. J Am Vet Med Assoc (1990) 0.76
Expression of feline recombinant interferon-gamma in baculovirus and demonstration of biological activity. Vet Immunol Immunopathol (1998) 0.76
Human blood pressure determination by sphygmomanometry. Circulation (1993) 7.88
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
The effects of explicit timing and feedback on compositional response rate in elementary school children. J Appl Behav Anal (1974) 3.56
Public health informatics: how information-age technology can strengthen public health. Annu Rev Public Health (1995) 3.10
Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature (2000) 2.41
Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol (1998) 2.40
Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence for the recombinational origin of subgroup B viruses. J Virol (1986) 2.34
Is screening for tuberculosis acceptable to immigrants? A qualitative study. J Public Health (Oxf) (2006) 2.28
Transduction and rearrangement of the myc gene by feline leukaemia virus in naturally occurring T-cell leukaemias. Nature (1984) 2.14
Homologous tyrosine phosphorylation sites in transformation-specific gene products of distinct avian sarcoma viruses. Nature (1981) 2.11
Comparison of six in-house tests for the rapid diagnosis of feline immunodeficiency and feline leukaemia virus infections. Vet Rec (2001) 2.08
Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII. Virology (1981) 2.03
Horizontal transmission of leukemia virus and leukemia in the cat. J Natl Cancer Inst (1973) 2.00
Hemidiaphragmatic paresis during interscalene brachial plexus block: effects on pulmonary function and chest wall mechanics. Anesth Analg (1992) 1.99
Maintenance of behavioral change in a cohort of homosexually active men. AIDS (1992) 1.77
Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J Cell Physiol (2000) 1.76
Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc Natl Acad Sci U S A (1997) 1.69
Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage (1999) 1.68
Characterization of a 105,000 molecular weight gag-related phosphoprotein from cells transformed by the defective avian sarcoma virus PRCII. Virology (1981) 1.67
The frequency of occurrence of feline leukaemia virus subgroups in cats. Int J Cancer (1978) 1.66
Determinants of the host range of feline leukaemia viruses. J Gen Virol (1973) 1.64
Biology of feline leukemia virus in the natural environment. Cancer Res (1976) 1.59
Post-discharge surgical wound infection surveillance in a provincial hospital: follow-up rates, validity of data and review of the literature. ANZ J Surg (2001) 1.56
The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology (1998) 1.55
Identification of a new fibroblast growth factor receptor, FGFR5. Gene (2001) 1.54
Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: results of a case-control study. Eur J Cancer (1995) 1.52
Common mechanism of infection by lentiviruses. Nature (1997) 1.47
Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology (1996) 1.46
Relationship among Lewis phenotype, clotting factors, and other cardiovascular risk factors in young adults. J Lab Clin Med (1995) 1.46
Feline leukemia virus envelope gp70 of subgroups B and C defined by monoclonal antibodies with cytotoxic and neutralizing functions. J Immunol (1983) 1.44
Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet Rec (1989) 1.43
Osteomyelitis: approaching the 1990s. Med J Aust (1990) 1.42
Plantar pressure differences between obese and non-obese adults: a biomechanical analysis. Int J Obes Relat Metab Disord (2001) 1.42
Transgenic science. Br Vet J (1994) 1.41
Vaccination against feline leukaemia virus. Vet Rec (1994) 1.39
'Tea trolley' difficult airway training. Anaesthesia (2015) 1.38
Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis (1993) 1.36
Recurrent haematuria in 17 children. Br Med J (1969) 1.36
Persistence and transmission of natural type I feline coronavirus infection. J Gen Virol (2003) 1.36
Pain syndromes and etiologies in ambulatory AIDS patients. Pain (1997) 1.35
Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene (1995) 1.35
Defective endogenous proviruses are expressed in feline lymphoid cells: evidence for a role in natural resistance to subgroup B feline leukemia viruses. J Virol (1994) 1.34
Replication of cat leukemia virus in cell cultures. Nature (1968) 1.34
Partial dissociation of subgroup C phenotype and in vivo behaviour in feline leukaemia viruses with chimeric envelope genes. J Gen Virol (1992) 1.33
Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS (1991) 1.33
Temporal patterns in the acoustic signals of beaked whales at Cross Seamount. Biol Lett (2008) 1.30
The pathogenicity and defectiveness of PRCII: a new type of avian sarcoma virus. Virology (1981) 1.28
Feline leukemia-virus infection of kittens: mortality associated with atrophy of the thymus and lymphoid depletion. J Natl Cancer Inst (1971) 1.25
Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology (1991) 1.25
Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene (2001) 1.25
Isolation of the nucleic acid of feline leukemia virus. Virology (1971) 1.25
Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. J Gen Virol (1993) 1.24
A study of naturally occurring feline coronavirus infections in kittens. Vet Rec (1992) 1.24
Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73, and Fujinami viruses. Proc Natl Acad Sci U S A (1981) 1.24
Esh avian sarcoma virus codes for a gag-linked transformation-specific protein with an associated protein kinase activity. Virology (1981) 1.23
A third class of avian sarcoma viruses, defined by related transformation-specific proteins of Yamaguchi 73 and Esh sarcoma viruses. Proc Natl Acad Sci U S A (1981) 1.22
Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. J Immunol (1985) 1.22
cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J Neurochem (2003) 1.21
Influence of ORF2 on host cell tropism of feline immunodeficiency virus. Virology (1996) 1.21
Cell-free translation of avian erythroblastosis virus RNA yields two specific and distinct proteins with molecular weights of 75,000 and 40,000. Virology (1980) 1.21
Differential growth and transmission in cats of feline leukaemia viruses of subgroups A and B. Int J Cancer (1978) 1.21
Preventing recurrent rheumatic fever: the role of register based programmes. Heart (2005) 1.20
The second extracellular loop of CXCR4 determines its function as a receptor for feline immunodeficiency virus. J Virol (1998) 1.19
Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. J Gen Virol (1997) 1.19
Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1998) 1.19
Control of endemic MRSA-what is the evidence? A personal view. J Hosp Infect (2004) 1.18
Detection of human herpesvirus-6 DNA in peripheral blood and saliva. J Med Virol (1990) 1.17
Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. Immunology (1993) 1.17
Structural diversity and nuclear protein binding sites in the long terminal repeats of feline leukemia virus. J Virol (1990) 1.17
Validation of the acuity card procedure for assessment of infants with ocular disorders. Ophthalmology (1987) 1.16
Lymphocytotoxic strains of feline leukemia virus induce apoptosis in feline T4-thymic lymphoma cells. Lab Invest (1992) 1.16
Spontaneously productive C-type retrovirus infection of fish cell lines. J Gen Virol (1991) 1.15
A monoclonal antibody which blocks infection with feline immunodeficiency virus identifies a possible non-CD4 receptor. J Virol (1993) 1.15
Myristoylation-dependent binding of HIV-1 Nef to CD4. J Mol Biol (1994) 1.15
Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol (1996) 1.15
Serological responses of cats to feline immunodeficiency virus. AIDS (1990) 1.14
Selective effect of feline leukaemia virus on early erythroid precursors. Nature (1982) 1.12
Cytogenetic and molecular analysis of inv dup(15) chromosomes observed in two patients with autistic disorder and mental retardation. Am J Med Genet (1996) 1.12
Retroviral transduction of T-cell antigen receptor beta-chain and myc genes. Nature (1987) 1.11
Complete nucleotide sequence and transcriptional analysis of snakehead fish retrovirus. J Virol (1996) 1.11
Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol (1995) 1.11
Modulation of feline immunodeficiency virus infection by stromal cell-derived factor. J Virol (1998) 1.11
Interaction between feline leukaemia virus subgroups in the pathogenesis of erythroid hypoplasia. Int J Cancer (1984) 1.10
Identification of a putative cellular receptor for feline immunodeficiency virus as the feline homologue of CD9. Immunology (1994) 1.09
Deletion of the N-terminus of murine map2 by gene targeting disrupts hippocampal ca1 neuron architecture and alters contextual memory. Neuroscience (2003) 1.09